Bristol-Myers Squibb Compnay

Bristol-Myers Squibb

Syngene International Limited

Tianan Fang

James R Corte

Wu Yang

Yufeng Wang

Donald J P Pinto

William R Ewing

Leon M Smith, Ii

Andrew K Dilger

Kumar Balashanmuga Pabbisetty

Jun Li

Yan Shi

Peter Tai Wah Cheng

Michael J Orwat

Hao Zhang

Joanne M Smallheer

Ruth Richmond Wexler

Jun Shi

Yeheng Zhu

Shiwei Tao

Lawrence J Kennedy

Indawati De Lucca

Mimi Lifen Quan

Paul Joseph Gilligan

Carl P Decicco

Karen Anita Rossi

Zilun Hu

Yoon T Jeon

Robert F Kaltenbach, Iii

Kumaravel Selvakumar

Steven J Walker

Ying Wang

Jon J Hangeland

Donald J Pinto

Sutjano Jusuf

Suresh Dhanusu

Ramesh Babu Reddigunta

Ruth R Wexler

Robert F Kaltenbach

Donald Jp Pinto

Ramesh Badu Reddigunta

Miml L Quan

Iii Robert F Kaltenbach

Donald JP Pinto

Leon M Smith Ii

Leon M Ii Smith

Robert F Iii Kaltenbach

Donald JP Pinto Pinto

Ii Smith Leon M

Yoon Jeon

Karen A Rossi

Mimi L Quan

Peter Tai Cheng

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Pyrimidinones as factor XIA inhibitors

The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Macrocycles as factor xia inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists

The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Cyclohexyl acid pyrazole azoles as LPA antagonists

The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Cyclohexyl acid triazole azoles as LPA antagonists

Cyclohexyl acid triazole azines as LPA antagonists

Macrocycles as factor XIA inhibitors

The present invention provides compounds of Formula (1): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Macrocycles as factor XIa inhibitors

Pyrimidinones as factor XIa inhibitors

The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Macrocyclic factor XIa inhibitors bearing heterocyclic groups

The present invention provides compounds of Formula (V):  or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Dihydropyridone P1 as factor XIa inhibitors

Growing community of inventors

Newtown, PA, United States of America

Tianan Fang